XANTUS, a prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

XANTUS is the first large, international prospective study to describe rivaroxaban use in a broad patient population with non-valvular atrial fibrillation.Out of 6784 patients, over 96% patients receiving rivaroxaban did not experience any of the outcomes of stroke/systemic embolism, treatment-emergent major bleeding or all-cause death.In XANTUS, rivaroxaban demonstrated low rates of stroke/ systemic embolism and major bleeding, including intracranial and gastrointestinal bleeding.Treatment persistence and patient satisfaction were high, namely 80% of patients remained on rivaroxaban and 75% reported they were satisfied with their treatment at one year.